由于人群中一般不存在针对黑猩猩型腺病毒的预存免疫，该类病毒载体的免疫效果优于常见的人血清型腺病毒如AdHu5。因此，近年来，黑猩猩型腺病毒成为新型疫苗载体的首选。黑猩猩型腺病毒分离鉴定有近100种，其中部分被应用于基础研究甚至进入临床试验。但由于构建技术等原因，该类载体在应用于疫苗研发之前并没有经过系统筛选、比较，至今尚未根据体液免疫、细胞免疫、炎症反应等综合评价来确定最佳黑猩猩型疫苗载体。因此，该类病毒作为疫苗载体的免疫学特性缺乏系统深入的研究，特别缺乏黑猩猩型腺病毒载体与常见的人血清型腺病毒载体、以及多种黑猩猩型腺病毒载体之间全方位的比较研究。这些研究对于筛选理想的黑猩猩型腺病毒载体或优化疫苗载体、提高疫苗免疫效果至关重要。本项目拟利用我们的技术优势，以流感为模型，深入探讨黑猩猩型腺病毒作为疫苗载体的免疫机理，确定腺病毒疫苗载体的筛选标准，为新型、高效疫苗研发奠定基础。

Since there is generally no pre-existing immunity to chimpanzee adenovirus in the population, vaccine vector originated from on chimpanzee adenovirus is superior to the common human serotype adenovirus such as AdHu5. Therefore, in recent years, chimpanzee adenovirus has become the first choice of a novel vaccine vector. Near 100 types of chimpanzee adenovirus have been isolated and identified, some of which have been used in basic research and even into clinical trials. However, due to the construction technology and other reasons, these vectors have not been systematically screened and comparative tested before their application to vaccine research and development. Up to now, we have no idea about which chimpanzee adenovirus is the best as vaccine vector, because there has no comprehensive evaluation on humoral immunity, cellular immunity and inflammatory response induced by these vectors. Therefore, it lacks the systematic and in-depth study on the immunological characteristics of these viruses as vaccine vectors, in particular the omnidirectional comparative study between the chimpanzee adenoviral vector and the common human serotype adenoviral vector, as well as a variety of chimpanzee adenoviral vectors. However, these studies are crucial for screening the ideal chimpanzee adenoviral vector or for optimizing the vaccine vector to improve the vaccine's efficacy. This grant application intends to take advantage of our technology and use influenza as a model to deeply explore the immune mechanism of chimpanzee adenovirus as a vaccine carrier and determine the screening criteria of adenoviral vectors, so as to pave the way for the developing novel and efficient vaccines.